IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Letters in Drug Design and Discovery

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on September 3, 2024

Impact Score

2023-2024

1.23

h-Index

2023-2024

 37

Rank

2023-2024

 18837

SJR

2023-2024

 0.222

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Letters in Drug Design and Discovery
Abbreviation Lett. Drug Des. Discov.
Publication Type Journal
Subject Area, Categories, Scope Pharmaceutical Science (Q3); Drug Discovery (Q4); Molecular Medicine (Q4)
h-index 37
Overall Rank/Ranking 18837
SCImago Journal Rank (SJR) 0.222
Impact Score 1.23
Publisher Bentham Science Publishers B.V.
Country United Arab Emirates
ISSN 1875628X, 15701808
Best Quartile Q3
Coverage History 2005-2023




About Letters in Drug Design and Discovery


Letters in Drug Design and Discovery is a journal covering the technologies/fields/categories related to Pharmaceutical Science (Q3); Drug Discovery (Q4); Molecular Medicine (Q4). It is published by Bentham Science Publishers B.V.. The overall rank of Letters in Drug Design and Discovery is 18837. According to SCImago Journal Rank (SJR), this journal is ranked 0.222. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 37. The best quartile for this journal is Q3.

The ISSN of Letters in Drug Design and Discovery journal is 1875628X, 15701808. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Letters in Drug Design and Discovery is cited by a total of 360 articles during the last 3 years (Preceding 2023).


Letters in Drug Design and Discovery Impact IF 2023-2024


The Impact IF 2023 of Letters in Drug Design and Discovery is 1.23, which is computed in 2024 as per its definition. Letters in Drug Design and Discovery IF is increased by a factor of 0.15 and approximate percentage change is 13.89% when compared to preceding year 2022, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Letters in Drug Design and Discovery Impact IF 2024 Prediction


Impact IF 2023 of Letters in Drug Design and Discovery is 1.23. If the same upward trend persists, Impact IF may rise in 2024 as well.


Impact IF Trend


Year wise Impact IF of Letters in Drug Design and Discovery. Based on Scopus data.


Year Impact IF
2023/2024 Coming Soon
2023 1.23
2022 1.08
2021 0.98
2020 1.10
2019 1.14
2018 0.93
2017 0.88
2016 1.23
2015 1.06
2014 0.85

Letters in Drug Design and Discovery h-index


  Table Setting

Letters in Drug Design and Discovery has an h-index of 37. It means 37 articles of this journal have more than 37 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Letters in Drug Design and Discovery ISSN


The ISSN of Letters in Drug Design and Discovery is 1875628X, 15701808. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Letters in Drug Design and Discovery Rank and SCImago Journal Rank (SJR)


The overall rank of Letters in Drug Design and Discovery is 18837. According to SCImago Journal Rank (SJR), this journal is ranked 0.222. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Letters in Drug Design and Discovery by Year


Year SJR
2023/2024 Coming Soon
2023 0.222
2022 0.192
2021 0.213
2020 0.223
2019 0.240
2018 0.207
2017 0.247
2016 0.313
2015 0.324
2014 0.241

Ranking of Letters in Drug Design and Discovery by Year


Year Ranking
2023/2024 Coming Soon
2023 18837
2022 19611
2021 17941
2020 17995
2019 16567
2018 17500
2017 15173
2016 13144
2015 12735
2014 15178

Letters in Drug Design and Discovery Publisher


Table Setting

Letters in Drug Design and Discovery is published by Bentham Science Publishers B.V.. It's publishing house is located in United Arab Emirates. Coverage history of this journal is as following: 2005-2023. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Letters in Drug Design and Discovery is Lett. Drug Des. Discov.. This abbreviation ('Lett. Drug Des. Discov.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Letters in Drug Design and Discovery


If your research field is/are related to Pharmaceutical Science (Q3); Drug Discovery (Q4); Molecular Medicine (Q4), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Letters in Drug Design and Discovery?

Letters in Drug Design and Discovery latest impact IF is 1.23. It's evaluated in the year 2023. The highest and the lowest impact IF or impact score of this journal are 1.23 (2023) and 0.85 (2014), respectively, in the last 10 years. Moreover, its average IS is 1.05 in the previous 10 years.


What's the SCImago Journal Rank (SJR) of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery has an SJR (SCImago Journal Rank) of 0.222, according to the latest data. It is computed in the year 2024. In the past 10 years, this journal has recorded a range of SJR, with the highest being 0.324 in 2015 and the lowest being 0.192 in 2022. Furthermore, the average SJR of the Letters in Drug Design and Discovery over the previous 10-year period stands at 1.05.


What's the latest h-index of the Letters in Drug Design and Discovery?

The latest h-index of the Letters in Drug Design and Discovery is 37.


Who's the publisher of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery is published by the Bentham Science Publishers B.V., with its country of publication being the United Arab Emirates.


What's the current ranking of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery is currently ranked 18837 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 10 years, this journal has experienced varying rankings, reaching its highest position of 12735 in 2015 and its lowest position of 19611 in 2022.


What's the abbreviation or short name for the Letters in Drug Design and Discovery?

The standard ISO4 abbreviation for the Letters in Drug Design and Discovery is Lett. Drug Des. Discov..


Is the "Letters in Drug Design and Discovery" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Letters in Drug Design and Discovery is classified as a journal that the Bentham Science Publishers B.V. publishes.


What's the scope or major areas of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery encompasses the following areas:

  • Pharmaceutical Science
  • Drug Discovery
  • Molecular Medicine

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery is assigned the following International Standard Serial Numbers (ISSN): 1875628X, 15701808.


What's the best quartile of the Letters in Drug Design and Discovery?

The best quartile for the Letters in Drug Design and Discovery is Q3 (2023).


What's the coverage history of the Letters in Drug Design and Discovery?

The Letters in Drug Design and Discovery coverage history can be summarized as follows: 2005-2023.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Journal of Academic Ethics journal 10291 Springer Netherlands 30 2.62
SPE Production and Operations Symposium, Proceedings conference and proceedings 15907 21 0.00
Proceedings of the International Symposium on Power Semiconductor Devices and ICs conference and proceedings 7015 49 2.14
CESifo Economic Studies journal 9721 Oxford University Press 34 0.89
Marine Biology Research journal 14120 Taylor and Francis Ltd. 45 1.02
Journal of Education and Work journal 11494 Brill Academic Publishers 45 2.17
Socialism and Democracy journal 25103 Taylor and Francis Ltd. 18 0.12
European Journal of Education journal 4662 Wiley-Blackwell Publishing Ltd 59 3.64
Indian Phytopathology journal 15501 Springer Nature 16 1.09
Journal of Sociology journal 5238 SAGE Publications Ltd 62 2.22

Check complete list




Year wise Impact Score (IS) of Letters in Drug Design and Discovery

Impact Score Table

Year Impact Score (IS)
2024/2025 Coming Soon
2023 1.23
2022 1.08
2021 0.98
2020 1.10
2019 1.14
2018 0.93
2017 0.88
2016 1.23
2015 1.06
2014 0.85



Top Journals/Conferences in Pharmaceutical Science

Nano Today
Elsevier B.V. | Netherlands

Advanced Drug Delivery Reviews
Elsevier B.V. | Netherlands

Advanced healthcare materials
John Wiley and Sons Inc. | United States

Journal of Controlled Release
Elsevier B.V. | Netherlands

Journal of Nanobiotechnology
BioMed Central Ltd | United Kingdom

Asian Journal of Pharmaceutical Sciences
Shenyang Pharmaceutical University | China

Bioengineering and Translational Medicine
John Wiley & Sons Inc. | United States

Apoptosis : an international journal on programmed cell death
Springer Netherlands | Netherlands

International Journal of Nanomedicine
Dove Medical Press Ltd. | New Zealand

Phytomedicine
Elsevier GmbH | Germany

See All

Top Journals/Conferences in Drug Discovery

Nature Reviews Drug Discovery
Nature Publishing Group | United Kingdom

Protein and Cell
Oxford University Press | United Kingdom

Molecular Therapy
Cell Press | United States

Medicinal Research Reviews
John Wiley & Sons Inc. | United States

Cell Chemical Biology
Elsevier Inc. | United States

Emerging Microbes and Infections
Taylor and Francis Ltd. | United Kingdom

Natural Product Reports
Royal Society of Chemistry | United Kingdom

Journal of Medicinal Chemistry
American Chemical Society | United States

MedComm
John Wiley and Sons Inc. | United States

Molecular Therapy - Nucleic Acids
Cell Press | United States

See All

Top Journals/Conferences in Molecular Medicine

Nature Biotechnology
Nature Publishing Group | United Kingdom

Cell Stem Cell
Cell Press | United States

Molecular Cancer
BioMed Central Ltd | United Kingdom

Pharmacological Reviews
American Society for Pharmacology and Experimental Therapeutics | United States

Genome Medicine
BioMed Central Ltd | United Kingdom

EMBO Molecular Medicine
Springer | United Kingdom

Molecular Therapy
Cell Press | United States

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

Experimental and Molecular Medicine
Korean Society of Med. Biochemistry and Mol. Biology | South Korea

Trends in Molecular Medicine
Elsevier Ltd | United Kingdom

See All